Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Non-Current Debt (2016 - 2017)

Historic Non-Current Debt for Lineage Cell Therapeutics (LCTX) over the last 3 years, with Q4 2017 value amounting to $18000.0.

  • Lineage Cell Therapeutics' Non-Current Debt fell 8500.0% to $18000.0 in Q4 2017 from the same period last year, while for Dec 2017 it was $18000.0, marking a year-over-year decrease of 8500.0%. This contributed to the annual value of $18000.0 for FY2017, which is 8500.0% down from last year.
  • Lineage Cell Therapeutics' Non-Current Debt amounted to $18000.0 in Q4 2017, which was down 8500.0% from $44000.0 recorded in Q3 2017.
  • In the past 5 years, Lineage Cell Therapeutics' Non-Current Debt ranged from a high of $268000.0 in Q3 2015 and a low of $18000.0 during Q4 2017
  • Over the past 3 years, Lineage Cell Therapeutics' median Non-Current Debt value was $146500.0 (recorded in 2016), while the average stood at $142600.0.
  • Its Non-Current Debt has fluctuated over the past 5 years, first tumbled by 3544.78% in 2016, then crashed by 8500.0% in 2017.
  • Over the past 3 years, Lineage Cell Therapeutics' Non-Current Debt (Quarter) stood at $220000.0 in 2015, then plummeted by 45.45% to $120000.0 in 2016, then crashed by 85.0% to $18000.0 in 2017.
  • Its last three reported values are $18000.0 in Q4 2017, $44000.0 for Q3 2017, and $95000.0 during Q2 2017.